LGALS3 and non-small cell lung carcinoma: Moreover, GAL3 has been identified as a predictive factor for recurrence-free survival (RFS) in NSCLC patients receiving platinum-based adjuvant chemotherapy (AC) (Kusuhara et al., 2021[26]).